Previous close | 2.8700 |
Open | 2.8400 |
Bid | 2.8700 x 200 |
Ask | 2.9000 x 300 |
Day's range | 2.8310 - 2.9926 |
52-week range | 1.8650 - 40.5800 |
Volume | |
Avg. volume | 1,172,801 |
Market cap | 203.038M |
Beta (5Y monthly) | 0.58 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.2400 |
Earnings date | 25 Mar 2024 - 29 Mar 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 10.80 |
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semaglutide or VTX3232 alone SAN DIEGO, June 05, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences: Event: UBS Obesity Therapeutics DayLocation: VirtualDate: Thursday, May 23, 2024Time: 12:00-12:30 PM ET Event: Jefferies Glob
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced the appointment of industry veteran Matthew Moore as Chief Operating Officer. “I am excited to welcome Matt to the Ventyx leadership team,” said Raju Mohan, Chief Executive Officer. “He brings a wealth of expertise to V